Andrew Kuykendall, MD, discusses the background, methods, and design of a phase 2 study which evaluated fedratinib.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback